BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fuereder T, Minichsdorfer C, Mittlboeck M, Wagner C, Heller G, Putz EM, Oberndorfer F, Müllauer L, Aretin MB, Czerny C, Schwarz-Nemec U. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. Oral Oncol 2022;124:105634. [PMID: 34844042 DOI: 10.1016/j.oraloncology.2021.105634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Balachander K, Paramasivam A. Anti-PD-1 agent: A promising immunotherapy drug for oral cancer? Oral Oncol 2022;132:105997. [PMID: 35772187 DOI: 10.1016/j.oraloncology.2022.105997] [Reference Citation Analysis]
2 Yang CC, Lien CF, Hwang TZ, Wang CC, Wang CC, Shih YC, Yeh SA, Hsieh MC. Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa. Cancers (Basel) 2022;14:2351. [PMID: 35625956 DOI: 10.3390/cancers14102351] [Reference Citation Analysis]